Entain plc (LSE: ENT), the global sports-betting and gaming group, formerly known as GVC Holdings PLC, confirms that the appointment of Robert Hoskin, Entain s Chief Governance Officer, to the Company s board of directors will take effect from 1 January 2021. This follows the announcement on 22 October 2020 setting out his proposed appointment. The Company also announces the departure of Jane Anscombe as Non-Executive Director, with effect from 31 December 2020, to pursue other opportunities. Jane joined the Board in June 2017 and has chaired the Remuneration Committee and served on the Nomination, CSR and Audit Committees. Jane s successor as Remuneration Committee Chair will be announced in due course.
A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Date Time
John Ryan named Senior Vice President and General Counsel at Dana-Farber Cancer Institute
Dana-Farber Cancer Institute has appointed John Ryan to be its next Senior Vice President, General Counsel and Chief Governance Officer, effective December 14.
Ryan has extensive expertise representing health care and life sciences organizations in public company and non-profit settings. He has managed a wide range of legal matters, including medical research and technology, clinical care, IP protection and international expansion.
“John’s sharp mind and deep understanding of the full range of legal issues affecting a complex organization such as Dana-Farber will be a tremendous asset in helping advance our patient care and research goals,” said Laurie H. Glimcher, MD, president and CEO, Dana-Farber Cancer Institute. “I look forward to working with him and the excellent legal team here that he is joining.”